Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Taneja

Showing results (201-210 of 845) with videos related to

Pageof 85
Sort By:
The Journal of Urology|July 13, 2012
Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialSamir S Taneja
The Journal of Urology|July 13, 2012
Re: Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinomaSamir S Taneja
The Journal of Urology|June 25, 2019
Re: Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends across Risk Groups in the United States, 2010-2015Samir S Taneja
The Journal of Urology|June 25, 2019
Re: Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-Ultrasound Fusion Targeted BiopsiesSamir S Taneja
The Urologic Clinics of North America|October 23, 2012
Urologic Clinics of North America. Castrate-resistant prostate cancer. ForewordSamir S Taneja
The Journal of Urology|October 13, 2012
Re: Centrally infiltrating renal masses on CT: differentiating intrarenal transitional cell carcinoma from centrally located renal cell carcinomaSamir S Taneja
The Journal of Urology|October 13, 2012
Re: Kidney size and cancer-specific survival for patients undergoing nephrectomy for pT1 clear cell renal cell carcinomaSamir S Taneja
The Journal of Urology|November 16, 2022
Urological Oncology: Prostate CancerSamir S Taneja
The Journal of Urology|November 8, 2024
Urological Oncology: Prostate CancerSamir S Taneja
The Journal of Urology|December 20, 2014
Re: The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened menSamir S Taneja
Pageof 85

Showing results (201-210 of 845) with videos related to

Sort By:
Pageof 85
The Journal of Urology|July 13, 2012
Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialSamir S Taneja
The Journal of Urology|July 13, 2012
Re: Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinomaSamir S Taneja
The Journal of Urology|June 25, 2019
Re: Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends across Risk Groups in the United States, 2010-2015Samir S Taneja
The Journal of Urology|June 25, 2019
Re: Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-Ultrasound Fusion Targeted BiopsiesSamir S Taneja
The Urologic Clinics of North America|October 23, 2012
Urologic Clinics of North America. Castrate-resistant prostate cancer. ForewordSamir S Taneja
The Journal of Urology|October 13, 2012
Re: Centrally infiltrating renal masses on CT: differentiating intrarenal transitional cell carcinoma from centrally located renal cell carcinomaSamir S Taneja
The Journal of Urology|October 13, 2012
Re: Kidney size and cancer-specific survival for patients undergoing nephrectomy for pT1 clear cell renal cell carcinomaSamir S Taneja
The Journal of Urology|November 16, 2022
Urological Oncology: Prostate CancerSamir S Taneja
The Journal of Urology|November 8, 2024
Urological Oncology: Prostate CancerSamir S Taneja
The Journal of Urology|December 20, 2014
Re: The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened menSamir S Taneja
Pageof 85